Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention01:27

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world optimization of cutoff values for enzyme immunoassay-based plasma-free fractionated metanephrines for the diagnosis of pheochromocytoma and paraganglioma: a multicenter retrospective study.

Endocrine journal·2026
Same author

14-3-3ζ interacts with DNA-binding domain of FOXO3a and competitively dissociates DNA by dual-motif tethering.

Nature communications·2026
Same author

Early initiation of guideline-directed medical therapy in patients with cardiogenic shock supported with Impella<sup>®</sup>: a two-center retrospective study.

BMC cardiovascular disorders·2025
Same author

Trends in the Management of Patients with Type 2 Diabetes Mellitus by Japanese Practitioners.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2025
Same author

Benzaldehyde suppresses epithelial-mesenchymal plasticity and overcomes treatment resistance in cancer by targeting the interaction of 14-3-3ζ with H3S28ph.

British journal of cancer·2025
Same author

Effect of blood pressure on recovery outcomes in inpatients with atherothrombotic infarction: A retrospective cross-sectional study.

Medicine·2025

Related Experiment Video

Updated: May 8, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Alkalizer administration improves renal function in hyperuricemia associated with obesity.

Jun Saito1, Yoko Matsuzawa, Hiroko Ito

  • 1Division of Endocrinology and Metabolism, Endocrinology and Diabetic center, Department of Medicine, Yokohama Rosai Hospital.

Japanese Clinical Medicine
|August 23, 2013
PubMed
Summary

Combining citrate with allopurinol improved kidney function and lowered uric acid in obese patients with hyperuricemia. This combination therapy showed potential benefits for metabolic syndrome patients.

Keywords:
Obesityalkalizercitratehyperuricemiarenal function

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Related Experiment Videos

Last Updated: May 8, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Area of Science:

  • Nephrology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Hyperuricemia is linked to obesity and metabolic syndrome (MetS), potentially impacting renal function.
  • Allopurinol is a xanthine oxidase inhibitor used to treat hyperuricemia.
  • Citrate, an alkalizer, may have beneficial effects on renal health.

Purpose of the Study:

  • To evaluate the combined effect of citrate and allopurinol on renal function and uric acid levels.
  • To assess the impact of this combination therapy on lipid profiles in obese patients with hyperuricemia and/or MetS.
  • To compare combination therapy with allopurinol monotherapy.

Main Methods:

  • Prospective randomized controlled study involving obese patients (BMI > 25 kg/m²).
  • Patients were randomized to allopurinol monotherapy or combination therapy with citrate.
  • Measurements included creatinine clearance (Ccr), serum uric acid, and lipid profiles before and after 12 weeks of treatment.

Main Results:

  • Combination therapy significantly increased Ccr and decreased serum uric acid in obese patients.
  • In patients with MetS, combination therapy showed a trend towards increased Ccr and decreased uric acid.
  • Triglyceride levels tended to improve more in the combination therapy group compared to monotherapy.

Conclusions:

  • Combination therapy with citrate and allopurinol effectively improves renal function and reduces uric acid in obese patients with hyperuricemia.
  • The combination therapy presents a promising approach for managing hyperuricemia and associated renal dysfunction in obesity and metabolic syndrome.
  • Further investigation into the lipid-modulating effects of this combination is warranted.